# A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Study · id `cardio:ct-nct03811561` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03811561](<https://clinicaltrials.gov/study/NCT03811561>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03811561

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT03811561. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-08 (actual); primary completion 2027-11-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT03811561, source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)
- Started: 2019-05-08 (actual) (ClinicalTrials.gov record NCT03811561, source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2027-11-07 (anticipated) (ClinicalTrials.gov record NCT03811561, source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)
- Completion: 2027-11-07 (anticipated) (ClinicalTrials.gov record NCT03811561, source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)
- Countries: United States; Brazil; Bulgaria; Canada; Czechia; Germany; Greece; India; Israel; Latvia; Mexico; Poland; Portugal; Romania; Russia; Serbia; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT03811561, source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03811561-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- Acronym: FOCUS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 9590af99a4d588adc220aa307547dffaf822533dc1c26f69fb5c8061d94e4a99
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
